HENDERSON, Nev., Sept. 17, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) (NYSE:VNRX) (together with affiliates "Volition"), a multi-national epigenetics company, as part of the Government-funded DETECSEPS Consortium in France, today shares further details about the official launch of the project on the early detection of sepsis.

DETECSEPS aligns with Volition's core purpose – to revolutionize the diagnosis and monitoring of life-altering diseases such as sepsis.

Sepsis is a dysregulated response of the body to an infection, responsible for the failure of one or more organs and which can quickly become life-threatening. Worldwide, it is estimated that this pathology is responsible for 21 million deaths per year¹. Rapid detection is therefore crucial to improve care and reduce mortality.

Cameron Reynolds, Chief Executive Officer, Volition, commented:

"I believe this is an exceptional vote of confidence in our Nu.Q® NETs platform. We are honored to be part of the DETECSEPS Consortium and to celebrate the major milestone of the program's official launch."

The DETECSEPS program aims to identify on arrival into the Emergency Department which patients with suspected infection are at risk of developing sepsis and require hospital care and which patients can be safely redirected home.

The objective is to allow earlier care and a more accurate referral of each patient.

Initiated by the IHU Sepsis, directed by Professor Djillali Annane of the Raymond-Poincaré Hospital AP-HP, DETECSEPS brings together within the same consortium the AP-HP, the project's coordinating institution and sponsor of the clinical trials, the Hospices Civils de Lyon and the industrial partners IDS France and Volition.

The strategy is based on an innovative combination:

The National Early Warning Score (NEWS) 2 clinical score to quickly assess the patient's condition upon arrival at the emergency department.
Volition's blood biomarker Nu.Q® NETs H3.1, capable of quantifying NETosis, an immune mechanism linked to sepsis.
The i10 device from IDS to automate the Volition biomarker for a quick and accurate result.

With government funding of €6.3 million (~7.3million), DETECSEPS will evaluate this strategy in 1,000 patients in real-life care settings. If the results are conclusive, this approach could profoundly change the journey of patients consulting for suspected infection by speeding up the care of those at risk, avoiding hospitalizations and improving the fluidity of emergency services. Its large-scale deployment could also help reduce the socio-economic costs and environmental impact associated with care pathways.

Prof. Marion Douplat, Head of the Emergency Department at Lyon Sud Hospital – HCL commented:

"Sepsis remains one of the main medical emergencies we face on a daily basis. Every hour saved in its identification can have a major impact on patients' prognosis.

"With DETECSEPS, we want to take a new step forward by combining the clinical evaluation carried out on arrival in the emergency room with an innovative biomarker, Nu.Q® NETs H3.1, that will make it possible to identify patients at risk earlier.

"This project perfectly illustrates the strength of translational research: to bring out innovations resulting from research to integrate them quickly into care pathways."

Prof. Léa Payen-Gay, Laboratory of Pharmacology, Toxicology and Pharmacogenetics, Department of Multisite Biochemistry and Molecular Biology (LBMMS) – HCL added:

"The collaboration between the Hospices Civils de Lyon and the companies Volition and IDS has been developed since 2020 around the evaluation of Nu.Q® technologies. It combines the clinical and biological expertise of HCL with Volition's technological know-how in the detection and characterization of circulating nucleosome biomarkers, particularly in the fields of oncology and sepsis.

"This collaboration has gradually extended to the study of NETosis and sepsis, with the ambition of validating innovative biomarkers in real healthcare conditions.

"In particular, it provides for the integration of the test on the local biochemistry platforms of the HCL's multi-site Medical Biology Laboratory, in order to evaluate its analytical performance, robustness and clinical applicability.

"It now constitutes a major scientific, technological and human basis for the DETECSEPS project, which evaluates the biomarker Nu.Q® NETs H3.1 in the emergency departments of the HCL and the AP-HP, with the aim of improving the early detection of sepsis and patient care."

Mr. Ed Combes, Managing Director – IDS France said:

"We are honored to be part of this consortium of excellence alongside HCL, AP-HP, IHU SEPSIS and Volition.

"The IDS i10 instrument, designed and manufactured in France, provides the essential technological link to transform the potential of the Nu.Q® NETs biomarker into a safe diagnostic routine.

"The elements are in place for a significant contribution to improving the early detection of sepsis."

Gray, Authia P et al. Global, regional, and national sepsis incidence and mortality, 1990–2021: a systemic analysis. The Lancet Global Health, 2025; 13(12): e2013-e2026. doi: 10.1016/s2214-109x(25)00356-0

About the Consortium

The DETECSEPS project was winner of the "Challenge Prevention" call for proposals launched by the French Health Innovation Agency and operated by the Banque Publique d'Investissement, as part of the France 2030 plan.

Initiated by the IHU Sepsis, led by Prof. Djillali Annane of the Raymond-Poincaré Hospital AP-HP, DETECSEPS brings together within the same consortium the AP-HP, the project's coordinating institution and sponsor of the clinical trials, the Hospices Civils de Lyon and the industrial partners IDS France and Volition who have been involved in several IHU projects. The project reflects one of the IHU's central missions: to accelerate the transition from scientific discoveries to solutions that can be directly used at the patient's bedside.

For this project, the AP-HP is mobilizing several care services and research teams contributing to the management of sepsis. The DETECSEPS project will more specifically mobilize the emergency departments of the Bichat-Claude-Bernard and Ambroise Paré AP-HP hospitals, as well as the reference medical biology laboratories of these two sites, which contribute to the National Reference Centers (CNR) in the fight against infectious diseases. The AP-HP also provides methodological support and biostatistical analysis for the project (Department of Biostatistics of the Saint-Louis Hospital AP-HP, URC Saint Louis), medico-economic (URCEco, Hôtel-Dieu AP-HP) and public health (Public Health Department of the Raymond-Poincaré Hospital AP-HP).

As industry partners, Volition will provide the sole biomarker, Nu.Q® NETs H3.1 and IDS France, part of Revvity, will provide the Immunodiagnostic Systems (IDS) i10® automated analyzer.

About Volition

Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.

Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.

Volition is providing the Nu.Q® H3.1 Assay pro-bono to enable this important evaluation.

The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.

Media Enquiries:

Louise Batchelor, Volition, mediarelations@volition.com, +44 (0)7557 774620

Safe Harbor Statement

Statements in this press release or associated video or link may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition's expectations regarding future publications, Volition's success in securing licensing and/or distribution agreements with third parties for its products, and Volition's expectations regarding the terms of such agreements. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; Volition's failure to achieve healthcare system or insurance plan reimbursement for its products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nu.Q^®, Nucleosomics™, Capture-PCR™, Capture-Seq™ and rNuQ™ and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release or associated video or link are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.

View original content to download multimedia:https://www.prnewswire.com/news-releases/volitionrx-shares-further-details-and-video-of-the-detecseps-program-launch-in-france-302881991.html

SOURCE VolitionRx Limited